Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Janssen Research & Development, LLC
Atul Deodhar; Philip S Helliwell; Wolf-Henning Boehncke; Alexa P Kollmeier; Elizabeth C Hsia; Ramanand A Subramanian; Xie L Xu; Shihong Sheng; Prasheen Agarwal; Bei Zhou; Yanli Zhuang; Christopher T Ritchlin; DISCOVER-1 Study Group
Clinical Biostatistics, Janssen Research and Development, Spring House, PA, USA. ; Clinical Biostatistics, Janssen Research and Development, Spring House, PA, USA.